Current through Register Vol. 50, No. 9, September 20, 2024
A.
Policy Basis. Research conducted and authorized by the DHH will meet all
applicable federal and state laws and regulations, accreditation standards, and
professional codes of ethics. These policies derive primarily from 45 CFR, Part
46, Protection of Human Subjects and are also consonant with 21 CFR, Parts 50
and 56, adopted by the Food and Drug Administration. (Both sets of regulations
were effective on August 19, 1991.) 45 CFR, Part 46 is applicable to other DHHS
components, including the Health Care Financing Authority (Medical Assistance
Programs).
B. Establishment of
Institutional Review Board (IRB). There is hereby established a DHH IRB to
review and evaluate all proposed research projects.
1. Twenty-four hour facilities may either
utilize these policies as written or amend them to provide for an in-house IRB
for initial assessment of research projects prior to submission to the DHH IRB
for final review.
2. All research
involving DHH consumers, employees, or services in the community and in
institutions will be reviewed by the DHH IRB before it is submitted to the
secretary or designee for final approval.
3. The IRB is a permanent standing committee
which meets quarterly or as needed.
4. The membership shall consist of at least
seven members, appointed by the secretary, partly from recommendations by the
assistant secretaries and the director of the BHSF:
a. the director of research and development
or his/her designee shall serve as permanent chairperson of the IRB. In the
event of an extended absence from duty of the permanent chair, the secretary
shall appoint a temporary replacement to serve during that period;
b. each office and the BHSF shall have at
least one member;
c. relevant
professional disciplines shall be represented in the membership;
d. at least one member shall be a direct
service provider;
e. one member
shall not be employed by the DHH. If possible, this member should be an
ethicist (specialist in ethics) or an attorney;
f. at least one member shall be either a
primary consumer, or a family member, or an advocate;
g. at least one member's primary concerns
shall be in science areas and at least one member's primary concerns shall be
in nonscientific areas. If not selected under
§2509. B.4 e, an attorney
or ethicist should fill the latter slot;
5. The IRB may, in its discretion, invite
individuals with competence in special areas to assist in the review of issues
which require expertise beyond or in addition to that available to the IRB.
Such individuals shall not vote with the IRB.
6. IRB members should have appropriate
research training, experience or interest. Membership should also sufficiently
represent the cultural, ethnic, and gender diversity of the state and be
sensitive to diverse community attitudes.
7. Except for the chair, members shall be
appointed for one-year terms and may be reappointed.
8. No IRB member may participate in the
initial or continuing review of any project in which the member has a
conflicting interest, except to provide information requested by the
IRB.
9. Once constituted, the IRB
shall adopt written bylaws and guidelines/application materials for conducting
research in DHH operated/funded programs or facilities.
10. Research approved by the Office of Public
Health's (OPH) IRB prior to the adoption of these policies does not require DHH
IRB approval. However, copies of proposals approved by the OPH IRB shall be
provided to the chair of the DHH IRB.
C. IRB Review Process. Prior to authorization
and initiation of research, an IRB meeting shall be convened to conduct a
detailed review of the project in order to determine that all of the following
requirements are met.
1. Proposal
incorporates procedures designed to minimize the risk to participants. Risks to
subjects are minimized by using procedures which are consistent with sound
research design and do not unnecessarily expose subjects to risk and, whenever
appropriate, by using procedures already being performed on subjects for
diagnostic or treatment purposes.
2. Risks to subjects are reasonable in
relation to anticipated benefits and the importance of any knowledge that may
reasonably be expected to result. In evaluating risks and benefits, the IRB
should consider only those risks and benefits that may result from the
research, as distinguished from risks and benefits of therapies subjects would
receive even if not participating in the research. The IRB should not consider
possible long-range effects of applying knowledge gained in the research (e.g.,
possible effects of research on public policy) as among those research risks
that fall within its purview.
3.
Selection of subjects is equitable. In making this assessment, the IRB should
take into account the purposes and setting of the research. It should be
particularly cognizant of special problems of research involving vulnerable
populations, such as children, prisoners, pregnant women, mentally disabled
persons, or economically or educationally disadvantaged persons.
4. Research design minimizes possible
disruptive effects of project on organizational operation.
5. Research design is in compliance with
accepted ethical standards.
6.
Informed consent will be sought from each prospective subject or the subject's
legally authorized representative, in accordance with and to the extent
required in
§2509 E
7. Informed consent will be appropriately
documented, in accordance with and to the extent required by
§2509. E 1-5 of these
rules.
8. When appropriate, the
research plan provides monitoring of the data collected to ensure subjects'
safety.
9. Research proposal
contains requisite safeguards to protect the privacy of subjects and to
maintain the confidentiality of data.
10. Research proposal has been approved at
the appropriate program administrative level, beginning with the
program/facility.
D. IRB
Recommendations and Notification
1.
Researchers should be either present at the IRB meeting which considers their
proposals or available for questioning at an indicated phone number during that
time.
2. Following detailed review,
the IRB by majority vote approves (fully or provisionally) or disapproves the
research proposal.
a. Provisional approval
means that minor modifications, specified in writing by the IRB, must be
received by the chair within 30 days in order to recommend full
approval.
b. Proposals receiving
full approval are sent to the secretary or designee for authorization to begin
research.
3. The
secretary or the director of research and development will notify the
researcher in writing of the IRB's decision to approve or disapprove the
proposed research within 10 working days.
a.
If the proposal is not approved, the letter will indicate reasons for
disapproval and give the researcher an opportunity to respond in writing to the
IRB.
b. There are no appeals for
research proposals disapproved on the basis of ethical shortcomings or
potential harm to subjects.
c. No
research, subject to IRB review, can begin until written authorization from the
secretary or designee is received.
d. Research approved by the IRB may be
subject to further administrative review and approval or disapproval. However,
no administrator can approve research which has not been approved by the
IRB.
e. After approval, the IRB
shall review the research in progress at appropriate intervals, but not less
than once per year.
f. The IRB has
the authority to suspend or terminate approval of research that is not being
conducted in accordance with the IRB's requirements or that has been associated
with unexpected harm to subjects. Any suspension or termination of approval
shall be in writing, include the reasons for this action, and be reported
promptly to the investigator, appropriate agency officials, and the
secretary.
g. Cooperative research
refers to those projects covered by this Chapter which involve more than one
institution or agency. In the conduct of cooperative research projects, each
institution or agency is responsible for safeguarding the rights and welfare of
human subjects and for complying with 45 CFR, Part 46 . With the approval of
the DHH or agency head, an institution participating in a cooperative project
may enter into a joint review arrangement, rely upon the review of another
qualified IRB, or make similar arrangements for avoiding duplication of
effort.
4. Expedited
Review Procedure
a. Research that involves no
more than minimal risk and in which the only involvement of human subjects will
be in one or more of the following categories (carried out through standard
methods) may be reviewed by the IRB through an expedited review procedure.
Under this procedure, the review may be carried out by the IRB chairperson or
by one or more experienced reviewers designated by the chair from among IRB
members. In reviewing the research, the reviewers may exercise all of the
authority of the IRB except that they may not disapprove the research. Research
may be disapproved only after review in accordance with the nonexpedited
procedures set forth in
§2509. C. A report of all
research approved by expedited review will be presented by the chair to the
full IRB at its next regularly scheduled meeting. Categories of research which
may qualify for expedited review include:
i.
research conducted in established or commonly accepted educational settings,
involving normal educational practices (e.g., research on special education
instructional strategies);
ii.
research involving the use of educational tests, survey procedures, interview
procedures, or observation of public behavior if such research does not record
information or identifiers which can be linked to individual human
subjects;
iii. research involving
the collection or study of existing data, documents, records, pathological
specimens, or diagnostic specimens;
iv. research and demonstration projects which
are conducted by or subject to the approval of the secretary or heads of
programmatic offices and are designed to study, evaluate, or otherwise examine
public benefit of services or programs;
v. research conducted by faculty or students
at colleges/universities if all of the following conditions are met:
(a). a copy of the university's IRB policies
is on file with the DHH IRB;
(b).
university IRB's approval of the research is documented;
(c). a copy of the full research proposal is
included;
(d). for student
research, written approval of the project by both a faculty advisor and a DHH
staff sponsor must be provided;
vi. research approved by an IRB in 24-hour
facilities if requested via the chief executive officer of the facility to the
DHH IRB chair;
vii. requests from
investigators for minor changes in research approved less than one year prior
to such request;
viii. cooperative
research which has been approved by the IRB and head of an agency outside of
DHH.
b. The secretary or
agency heads may restrict, suspend, terminate, or choose not to authorize use
of the expedited review procedure.
E. Informed Consent of Research Subjects.
Except as provided elsewhere in Chapter 25, no investigator may involve a human
being as a subject in research unless the investigator obtains the legally
effective informed consent of the subject or the subject's authorized
representative. An investigator shall seek such consent only under
circumstances that provide the prospective subject or the representative
sufficient opportunity to consider whether or not to participate and that
minimize the possibility of coercion or undue influence. The information that
is given to the subject or representative shall be in language easily
understandable to the subject or representative. No informed consent document
may include any exculpatory language through which the subject or
representative is made to waive or appear to waive any of the subject's legal
rights or the investigator, the sponsor, or the agency and its agents
are/appear to be released from liability for negligence.
1. Basic Elements of Informed Consent. Except
as provided below, the investigator shall provide each subject the following
information:
a. a statement that the study
involves research, an explanation of the purposes of the research and the
expected duration of the subject's participation, a description of the
procedures to be followed, and identification of any procedures which are
experimental;
b. a description of
any reasonably foreseeable risks or discomforts to the subject;
c. a description of any benefits to the
subject or to others which may reasonably be expected from the
research;
d. a disclosure of
appropriate alternative procedures or courses of treatment, if any, that might
be advantageous to the subject;
e.
a statement describing the extent, if any, to which confidentiality of records
identifying the subject will be maintained;
f. for research involving more than minimal
risk, explanations as to whether any compensation and medical treatment are
available if injury occurs and, if so, what they consist of, or where further
information may be obtained;
g. an
explanation of whom to contact for answers to pertinent questions about the
research and research subjects' rights, and whom to contact in the event of a
research related injury to the subject;
h. a statement that participation is
voluntary, refusal to participate will involve no penalty or loss of benefits
to which the subject is otherwise entitled, and the subject may discontinue
participation at any time without penalty or loss of benefits to which the
subject is otherwise entitled.
2. Additional Elements of Informed Consent.
When appropriate, one or more of the following elements of information shall
also be provided to each subject:
a. a
statement that the particular treatment or procedure may involve risk that is
currently unforeseeable;
b.
anticipated circumstances under which the subject's participation may be
terminated by the investigator without regard to the subject's
consent;
c. any additional costs to
the subject that may result from research participation;
d. the consequences of a subject's decision
to withdraw from the research and procedures for orderly termination of
participation by the subject;
e. a
statement that significant new findings developed during the course of the
research which may relate to the subject's willingness to continue
participation will be provided to the subject;
f. the approximate number of subjects
involved in the study.
3. Waiver of Informed Consent. The IRB may
waive the requirement to obtain informed consent provided that the IRB finds
and documents that:
a. the research or
demonstration project is to be conducted by or subject to the approval of state
government officials and is designed to study or evaluate public benefit of
services provided or funded by DHH;
b. such project deals with improving
procedures for obtaining benefits/services under those programs and/or
suggesting possible changes in or alternatives to those programs/procedures or
in the methods/levels of payment for benefits or services under those programs;
and
c. such research or projects
shall not involve identifying individual recipients of
services/benefits.
4.
Documentation of Informed Consent
a. Informed
consent shall be documented by the use of a written consent form approved by
the IRB and signed by the subject or the subject's legally authorized
representative. A copy shall be given to the person signing the form.
b. The written consent document must embody
the elements of informed consent required in
§2509. E.1 This form may
be read to the subject or the subject's legally authorized representative but,
in any event, the investigator shall give either the subject or the
representative adequate opportunity to read it before it is signed. An IRB
recommended informed consent document will be included in the
guidelines/application materials for conducting research in DHH operated/funded
programs or facilities.
c. The IRB
may waive the requirement for the investigator to obtain a signed consent form
for some or all subjects if it finds either:
i. that the only record linking the subject
and the research would be the consent document and the principal risk would be
the potential harm resulting from a breach of confidentiality. Each subject
will be asked if he/she wants documentation linking him/her with the research,
and the subject's wish shall govern; or
ii. that the research presents no more than
minimal risk of harm to subjects and involves no procedures for which written
consent is normally required outside of the research context.
d. In cases in which the
documentation requirement is waived, the IRB may require the investigator to
provide subjects with a written statement regarding the research.
5. The IRB shall demand additional
protection and informed consent rights if the research involves fetuses,
pregnant women and human in-vitro fertilization ( 45 CFR46:201-211), prisoners
( 45 CFR 46:301-306), or children ( 45 CFR 46:401-409).
F. Responsibilities of Research
Investigators. In addition to all of the requirements detailed in §2509,
researchers shall be responsible for the following.
1. Research investigators shall prepare and
submit a protocol giving a complete description of the proposed research.
a. The protocol shall include provisions for
adequate protection of the rights and welfare of prospective research subjects
and ensure that pertinent laws and regulations are observed.
b. Samples of proposed informed consent forms
shall be included with the protocol.
c. A completed DHH Application to Conduct
Research must be submitted with the protocol.
2. Research investigators shall obtain and
document appropriate administrative approval (beginning at the program/facility
level) to conduct research before the proposal is submitted to the DHH
IRB.
3. Prior to the beginning of
the research, the investigator shall communicate to impacted staff the purpose
and nature of the research.
4. Upon
completion of the research, the principal investigator shall attempt to remove
any confusion, misinformation, stress, physical discomfort, or other harmful
consequences, however unlikely, that may have arisen with respect to subjects
as a result of the research.
5.
Within 30 working days of the completion of the research, the principal
investigator shall communicate the outcome(s) and practical or theoretical
implications of the research project to the program administrator and, when
appropriate, program staff in a manner that they can understand.
6. The researcher shall submit progress
reports as requested by the IRB (at least annually). As soon as practicable
after completion of the research, but in no case longer than 90 working days
later, the research investigator shall submit to the IRB a written report,
which, at a minimum, shall include:
a. a firm
date on which a full, final report of research findings will be
submitted;
b. a succinct exposition
of the hypotheses of the research, the research design and methodologies, and
main findings of the research;
c.
an estimate of the validity of conclusions reached and some indication of areas
requiring additional research; and
d. specific plans for publishing results of
the research.
7. A final
report of the research as well as copies of any publications based upon the
research will be submitted to the IRB as soon as possible. The state owns the
final report, but prior permission of the IRB for the investigator to publish
results of the research is not required. The publication is the property of the
researcher and/or the medium in which it is published. However, failure to
provide the IRB with required periodic and final reports or publications based
on the research shall negatively impact that researchers's future research
shall negatively impact that researcher's future requests to conduct research
in DHH operated/funded programs or facilities.
G. Initiation of the Research Review Process
1. The first contact in the process should be
by the research investigator with the manager of the program or facility from
which subjects will be drawn.
2. If
the manager agrees that the research is feasible and desirable, the researcher
will obtain his/her written authorization and send the protocol to appropriate
staff at headquarters for consideration and approval by the assistant
secretaries or the director of BHSF.
3. The assistant secretaries or the director
of BHSF, in approving the research proposal, will certify that:
a. the research design is adequate and meets
acceptable scientific standards;
b.
appropriate ethical considerations have been identified and
discussed;
c. the proposal contains
provisions to minimize possible disruptive effects of the project on
organization's operation;
d. the
research will potentially benefit the participants directly or improve the
service system; and
e. the research
topic is compatible with the agency's research agenda.
4. The assistant secretaries or the director
of BHSF, after approval of the research, will submit the proposal to the IRB
for further consideration.
H. IRB Records
1. The IRB shall prepare and maintain
adequate documentation of IRB activities, including the following:
a. copies of all research proposals reviewed,
scientific evaluations, if any, that accompany the proposals, approved sample
consent documents, progress reports submitted by investigators, and reports of
injuries to subjects;
b. minutes of
IRB meetings in sufficient detail to show attendance at the meeting; actions
taken by the IRB; the vote on these actions, including the number of members
voting for, against, and abstaining; the basis for requiring changes in or
disapproving research; and a written summary of the discussion of controverted
issues and their resolution;
c.
records of continuing review activities;
d. copies of all correspondence between the
IRB and investigators;
e. a list of
IRB members identified by name; earned degrees; representative capacity;
indications of experience sufficient to describe each member's chief
anticipated contributions to IRB deliberations; and any employment or other
relationship between each member and the DHH;
f. written procedures for the IRB and
statements of significant new findings provided to subjects.
2. The records required by
§2509. H shall be
retained for at least three years, and records relating to research which is
conducted shall be retained for at least three years after completion of the
research. All records shall be accessible for inspection and copying by
authorized representatives of DHHS or the agency at reasonable times and in a
reasonable manner.
AUTHORITY NOTE:
Promulgated in accordance with 56 FR
28002.